高雄醫學大學圖書館 |

Targeting the Thyroid-Stimulating Hormone Receptor (TSHR) in Thyroid Cancer /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Targeting the Thyroid-Stimulating Hormone Receptor (TSHR) in Thyroid Cancer // Grayson Robert Gimblet.
Author:	Gimblet, Grayson Robert,
Description:	1 electronic resource (172 pages)
Notes:	Source: Dissertations Abstracts International, Volume: 86-12, Section: B.
基督教聖經之智慧書導讀 :	Radioactive iodine (RAI) has been effective in the treatment of thyroid cancer, the most common endocrine neoplasia, since its introduction into clinical use over eighty years ago. However, not all patients benefit from RAI. Up to 20% of patients with well-differentiated thyroid cancer (WDTC) become radioactive iodine refractory (RAI-R). These RAI-R patients have 5-year survival rates of 50% and 10-year survival rates of 10%. In addition, more aggressive subtypes including oncocytic thyroid carcinoma (OC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC) are less responsive to RAI therapy. Despite accounting for less than 5% of annual thyroid cancer cases, PDTC and ATC represent more than half of annual thyroid cancer mortality.To address the need for new diagnostic and therapeutic strategies in these patients, this study explores the thyroid-stimulating hormone receptor (TSHR) as an alternative target in thyroid cancer. We described the frequency of TSHR expression in OC (62%), PDTC (58%), and ATC (0%) relative to established expression patterns in WDTC (90%), with particular emphasis placed on expression patterns in RAI-R disease. As thyroid cancer loses endogenous TSHR expression in monolayer cell culture, we established cell lines with stable TSHR expression. We used these cell lines to evaluate TSHR-targeted radiopharmaceuticals. We designed PET radiopharmaceuticals based on two recombinant human thyroid-stimulating hormone analogues, TR1402 and thyrotropin-alfa, radiolabeled with 89Zr (t1/2 = 78.4 h, β+=23%). We performed in vitro assessments of these TSHR-targeted tracers including cell uptake, receptor blocking, internalization, and binding affinity. We evaluated tumor uptake and biodistribution with in vivo PET imaging and ex vivo biodistribution using a subcutaneous xenograft model established in male and female athymic nude mice. The results of these studies show targeting the TSHR is a promising approach for RAI-R and aggressive thyroid cancers. The PET tracers in this study can be used as the basis for future work to design a theranostic TSHR-targeted approach.
Contained By:	Dissertations Abstracts International86-12B.
Subject:	Oncology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31932654
ISBN:	9798315793366

Targeting the Thyroid-Stimulating Hormone Receptor (TSHR) in Thyroid Cancer /
Gimblet, Grayson Robert,

Targeting the Thyroid-Stimulating Hormone Receptor (TSHR) in Thyroid Cancer /Grayson Robert Gimblet. - 1 electronic resource (172 pages)

Source: Dissertations Abstracts International, Volume: 86-12, Section: B.

Radioactive iodine (RAI) has been effective in the treatment of thyroid cancer, the most common endocrine neoplasia, since its introduction into clinical use over eighty years ago. However, not all patients benefit from RAI. Up to 20% of patients with well-differentiated thyroid cancer (WDTC) become radioactive iodine refractory (RAI-R). These RAI-R patients have 5-year survival rates of 50% and 10-year survival rates of 10%. In addition, more aggressive subtypes including oncocytic thyroid carcinoma (OC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC) are less responsive to RAI therapy. Despite accounting for less than 5% of annual thyroid cancer cases, PDTC and ATC represent more than half of annual thyroid cancer mortality.To address the need for new diagnostic and therapeutic strategies in these patients, this study explores the thyroid-stimulating hormone receptor (TSHR) as an alternative target in thyroid cancer. We described the frequency of TSHR expression in OC (62%), PDTC (58%), and ATC (0%) relative to established expression patterns in WDTC (90%), with particular emphasis placed on expression patterns in RAI-R disease. As thyroid cancer loses endogenous TSHR expression in monolayer cell culture, we established cell lines with stable TSHR expression. We used these cell lines to evaluate TSHR-targeted radiopharmaceuticals. We designed PET radiopharmaceuticals based on two recombinant human thyroid-stimulating hormone analogues, TR1402 and thyrotropin-alfa, radiolabeled with 89Zr (t1/2 = 78.4 h, β+=23%). We performed in vitro assessments of these TSHR-targeted tracers including cell uptake, receptor blocking, internalization, and binding affinity. We evaluated tumor uptake and biodistribution with in vivo PET imaging and ex vivo biodistribution using a subcutaneous xenograft model established in male and female athymic nude mice. The results of these studies show targeting the TSHR is a promising approach for RAI-R and aggressive thyroid cancers. The PET tracers in this study can be used as the basis for future work to design a theranostic TSHR-targeted approach.

English

ISBN: 9798315793366Subjects--Topical Terms:

273823
Oncology.
Subjects--Index Terms:

Anaplastic thyroid carcinoma

Targeting the Thyroid-Stimulating Hormone Receptor (TSHR) in Thyroid Cancer /
LDR:03686nam a22004213i 4500 001 391485
005 20251124054805.5
006 m o d
007 cr|nu||||||||
008 251208s2025 miu||||||m |||||||eng d
020 $a 9798315793366
035 $a (MiAaPQD)AAI31932654
035 $a AAI31932654
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Gimblet, Grayson Robert, $e author. $3 524038
245 1 0 $a Targeting the Thyroid-Stimulating Hormone Receptor (TSHR) in Thyroid Cancer / $c Grayson Robert Gimblet.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2025
300 $a 1 electronic resource (172 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-12, Section: B.
500 $a Advisors: Lapi, Suzanne E. Committee members: Jaskula-Sztul, Renata; McConathy, Jonathan E.; Willey, Christopher D.; Larimer, Benjamin M.
502 $b Ph.D. $c The University of Alabama at Birmingham $d 2025.
520 $a Radioactive iodine (RAI) has been effective in the treatment of thyroid cancer, the most common endocrine neoplasia, since its introduction into clinical use over eighty years ago. However, not all patients benefit from RAI. Up to 20% of patients with well-differentiated thyroid cancer (WDTC) become radioactive iodine refractory (RAI-R). These RAI-R patients have 5-year survival rates of 50% and 10-year survival rates of 10%. In addition, more aggressive subtypes including oncocytic thyroid carcinoma (OC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC) are less responsive to RAI therapy. Despite accounting for less than 5% of annual thyroid cancer cases, PDTC and ATC represent more than half of annual thyroid cancer mortality.To address the need for new diagnostic and therapeutic strategies in these patients, this study explores the thyroid-stimulating hormone receptor (TSHR) as an alternative target in thyroid cancer. We described the frequency of TSHR expression in OC (62%), PDTC (58%), and ATC (0%) relative to established expression patterns in WDTC (90%), with particular emphasis placed on expression patterns in RAI-R disease. As thyroid cancer loses endogenous TSHR expression in monolayer cell culture, we established cell lines with stable TSHR expression. We used these cell lines to evaluate TSHR-targeted radiopharmaceuticals. We designed PET radiopharmaceuticals based on two recombinant human thyroid-stimulating hormone analogues, TR1402 and thyrotropin-alfa, radiolabeled with 89Zr (t1/2 = 78.4 h, β+=23%). We performed in vitro assessments of these TSHR-targeted tracers including cell uptake, receptor blocking, internalization, and binding affinity. We evaluated tumor uptake and biodistribution with in vivo PET imaging and ex vivo biodistribution using a subcutaneous xenograft model established in male and female athymic nude mice. The results of these studies show targeting the TSHR is a promising approach for RAI-R and aggressive thyroid cancers. The PET tracers in this study can be used as the basis for future work to design a theranostic TSHR-targeted approach.
546 $a English
590 $a School code: 0005
650 4 $2 96060 $a Oncology. $3 273823
650 4 $2 96060 $a Chemistry. $3 202365
650 4 $a Pharmaceutical sciences. $3 523812
653 $a Anaplastic thyroid carcinoma
653 $a Oncocytic thyroid carcinoma
653 $a Radioactive iodine
653 $a Thyroid cancer
690 $a 0572
690 $a 0485
690 $a 0992
710 2 $a The University of Alabama at Birmingham. $b Pharmacology and Toxicology. $e degree granting institution. $3 524039
720 1 $a Lapi, Suzanne E. $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-12B.
790 $a 0005
791 $a Ph.D.
792 $a 2025
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31932654